Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Intellia Therapeutics (NTLA) Receivables - Other (2016 - 2023)

Intellia Therapeutics has reported Receivables - Other over the past 9 years, most recently at $1.0 million for Q4 2023.

  • Quarterly Receivables - Other fell 37.5% to $1.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2023, down 37.5% year-over-year, with the annual reading at $1.0 million for FY2023, 900.0% up from the prior year.
  • Receivables - Other was $1.0 million for Q4 2023 at Intellia Therapeutics, roughly flat from $1.0 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $8.4 million in Q1 2020 and troughed at $100000.0 in Q4 2021.
  • The 5-year median for Receivables - Other is $1.1 million (2019), against an average of $2.0 million.
  • Year-over-year, Receivables - Other crashed 88.1% in 2021 and then soared 1500.0% in 2022.
  • A 5-year view of Receivables - Other shows it stood at $3.6 million in 2019, then crashed by 66.67% to $1.2 million in 2020, then crashed by 91.67% to $100000.0 in 2021, then soared by 1500.0% to $1.6 million in 2022, then plummeted by 37.5% to $1.0 million in 2023.
  • Per Business Quant, the three most recent readings for NTLA's Receivables - Other are $1.0 million (Q4 2023), $1.0 million (Q3 2023), and $1.4 million (Q2 2023).